XY Therapeutics ApS: Financial statements 2025
CVR: 41120681
Source: annual report 2025, Danish Business Authority
01/07/2024 – 30/06/2025
XY Therapeutics ApS (CVR 41120681) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 3,676,788 and a net result of DKK -2,096,400 compared with DKK -1,369,854 the year before. That is an increase of 37.2% compared with the year before. Equity in the 2025 report amounted to DKK -9,494,046. The company had 1 employee in the financial year.
- Gross Profit
- DKK 3,676,788
- Profit/Loss
- DKK -2,096,400
- Equity
- DKK -9,494,046
- Total Assets
- DKK 6,040,651
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 3.7M | -2.1M | -9.5M | 1 |
| 2024 | - | 2.7M | -1.4M | -7.4M | 1 |
| 2023 | - | 362K | -1.2M | -6M | 2 |
| 2022 | - | 627K | -2.4M | -4.9M | 2 |
Official annual report
How creditworthy is XY Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAbout XY Therapeutics ApS
XY Therapeutics ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Fertilitypro ApS. The management consists of Martin Blomberg Jensen. The company is owned by Holding Fertility4U ApS. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 3,676,788 and a net result of DKK -2,096,400 compared with DKK -1,369,854 the year before. Equity in the 2025 report amounted to DKK -9,494,046.